← Back to signals
MYGN
MYRIAD GENETICS INC
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
Days to cover (short int.)
2.0d↓-1.3%
as of 2026-10-30 · shares short vs 2026-09-30
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Glenview Capital | SC 13G/A | — | 0.0% | +89.7% vs SPY +87.5% abs | 2026-08-14 | ↗ |
| Glenview Capital | SC 13G | NEW | 5.3% | — | 2026-01-13 | ↗ |
Tracked Funds Holding (1)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Point72 | Steve Cohen | 3.2M | $14M |
Quarter-end 13F positions for the tracked funds holding this stock.